EORTC 22961 is the latest trial to investigate the optimum duration of adjuvant androgen deprivation therapy for patients with locally advanced prostate cancer. The results conclusively show superiority of long-term over short-term treatment, and the former protocol should, therefore, be considered standard of care in this setting.
This is a preview of subscription content, log in via an institution to check access.
References
Huggins, C., Stevens, R. E. Jr & Hodges, C. V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209–223 (1941).
Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).
van der Werf-Messing, B., Sourek-Zikova, V. & Blonk, D. I. Localized advanced carcinoma of the prostate: radiation therapy versus hormonal therapy. Int. J. Radiat. Oncol. Biol. Phys. 1, 1043–1048 (1976).
Zagars, G. K., Johnson, D. E., von Eschenbach, A. C. & Hussey, D. H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int. J. Radiat. Oncol. Biol. Phys. 14, 1085–1091 (1988).
Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285–1290 (2005).
Roach, M. III et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585–591 (2008).
Bolla, M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337, 295–300 (1997).
Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103–106 (2002).
Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J. Clin. Oncol. 21, 3972–3978 (2003).
Horwitz, E. M. et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26, 2497–2504 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Horwitz, E. Optimizing the duration of androgen deprivation therapy. Nat Rev Urol 6, 527–529 (2009). https://doi.org/10.1038/nrurol.2009.194
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.194
- Springer Nature Limited